Astrana Health, Inc. — Form 8-K
Filed September 23, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
Astrana Health raised its full-year 2026 Adjusted EBITDA guidance to $255–$280M (midpoint $267.5M) from prior guidance, citing Q2 2026 outperformance. Q2 2026 revenue was $972.5M (up 58% YoY), Adjusted EBITDA $68.9M, and free cash flow YTD $92.9M. The company reaffirmed full-year revenue guidance of $3,800–$4,100M and free cash flow guidance of $105–$132.5M. No specific counterparties, acquisitions, or material operational changes were announced in this filing.
Why this rating
Guidance raise on strong H1 execution is positive but routine for growth companies. ~$267.5M Adjusted EBITDA represents 2.4% of $1.1B market cap—meaningful but not transformational. Reinvestment into provider/payer growth suggests confidence, not a major strategic pivot.
See more from September 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.